Ascendis Pharma's TransCon CNP Shows Early Promise in Infant Achondroplasia Trial — Ascendis Pharma A/S

Event summary

Ascendis Pharma presented Week 52 data from the sentinel cohort of its reACHin trial, showing stable or improved foramen magnum stenosis in infants with achondroplasia treated with TransCon CNP.
Treatment with TransCon CNP increased linear growth, with a mean change in ACH-specific supine length Z-score of +0.42 from baseline through Week 52.
TransCon CNP was generally well tolerated, with no reports of injection site reactions over the 52-week treatment period.
The reACHin trial is a pivotal Phase 2, randomized, placebo-controlled trial evaluating the safety, tolerability, and efficacy of once-weekly TransCon CNP in infants aged 0 to <2 years with achondroplasia.
TransCon CNP, marketed as YUVIWEL, was approved by the FDA in February 2026 for pediatric patients 2 years of age and older with achondroplasia.

The big picture

Ascendis Pharma's TransCon CNP represents a significant advancement in the treatment of achondroplasia, a rare genetic condition affecting over 250,000 people worldwide. The positive data from the sentinel cohort of the reACHin trial underscores the potential of TransCon CNP to address critical medical complications in infants, positioning Ascendis as a key player in the rare disease space. The upcoming regulatory decision from the European Medicines Agency will be a pivotal moment for the company, potentially expanding its market reach and solidifying its leadership in pediatric rare disease treatments.

What we're watching

Regulatory Approval: Whether the European Medicines Agency will approve YUVIWEL in the fourth quarter of 2026, following its FDA approval in February 2026.
Clinical Efficacy: How the stabilization or improvement in foramen magnum stenosis observed in the sentinel cohort will translate into long-term benefits for infants with achondroplasia.
Market Expansion: The pace at which Ascendis Pharma can expand the use of TransCon CNP to younger patients, given the promising early data from the infant trial.